指南与共识肾癌与肾肿瘤

散发性肾血管平滑肌脂肪瘤的管理:现有证据的系统评价以指导欧洲泌尿外科学会肾细胞癌指南小组的推荐

Management of Sporadic Renal Angiomyolipomas: A Systematic Review of Available Evidence to Guide Recommendations from the European Association of Urology Renal Cell Carcinoma Guidelines Panel.
指南 / 共识 · Eur Urol Oncol · 2019-06-04

该系统评价纳入1990年1月1日至2017年6月30日文献,共43项研究(零项随机对照试验、9项非随机回顾性比较研究、34项单臂病例系列),评估散发性肾血管平滑肌脂肪瘤的主动监测、手术、选择性动脉栓塞和热消融的指征、疗效、危害及随访。主动监测系列中自发性出血报告为2%,5%接受主动治疗;选择性动脉栓塞似可缩小AML体积但30%需二次治疗;手术(尤其保留肾单位手术)在复发和需二次手术方面最有效。

要点

  • 主动监测系列中自发性出血报告为2%,5%接受主动治疗。
  • 选择性动脉栓塞似可缩小AML体积,但30%病例需二次治疗。
  • 手术(尤其保留肾单位手术)在复发和需二次手术方面最有效。

核心结论

  • 主动监测是最常选择的方案,占48%的病例,其次为手术31%和选择性动脉栓塞17%。
  • 选择性动脉栓塞似可缩小AML体积,但30%的病例需要二次治疗。
  • 手术(尤其保留肾单位手术)在复发和需二次手术方面是最有效的治疗。
  • AML大小与出血风险之间的关联仍不明确,因此传统的4厘米截断值本身不应触发主动治疗。
  • 尽管证据基础存在局限性和不确定性,这些发现可用于指导和 informing 临床实践,直至出现更可靠的数据。

研究设计与样本

  • 系统评价,检索Medline、Embase和Cochrane图书馆(1990年1月1日至2017年6月30日),遵循系统评价和Meta分析优先报告条目指南。
  • 未限制研究设计,纳入散发性AML患者。
  • 共识别2704篇文章,43篇符合纳入标准:零项随机对照试验、9项非随机回顾性比较研究、34项单臂病例系列。
  • 多数研究为回顾性、非对照,存在中至高偏倚风险。
  • 采用标准Cochrane方法进行偏倚风险评估。

主要发现

  • 主动监测系列中,自发性出血报告为2%的患者,5%接受了主动治疗。
  • 主动监测是最常选择的方案,占48%的病例,其次为手术31%和选择性动脉栓塞17%。
  • 选择性动脉栓塞似可缩小AML体积,但30%的病例需要二次治疗。
  • 手术(尤其保留肾单位手术)在复发和需二次手术方面是最有效的治疗。
  • 热消融是较少使用的选项。

关键数值与推荐

  • 主动监测系列中自发性出血报告为2%,主动治疗为5%。
  • 主动监测占48%的病例,手术占31%,选择性动脉栓塞占17%。
  • 选择性动脉栓塞后30%的病例需要二次治疗。
  • 传统的4厘米截断值本身不应触发主动治疗。

临床怎么用

  • 大多数小AML可以监测而无需任何主动治疗。
  • 对于需要治疗者,选项包括手术切除肿瘤或阻断其血供(选择性栓塞)。
  • 手术的复发率较低,需要重复手术操作的需求较低。
  • 传统的4厘米截断值本身不应触发主动治疗。

局限性

  • 多数研究为回顾性、非对照,存在中至高偏倚风险。
  • 证据基础存在局限性和不确定性。
  • AML大小与出血风险之间的关联仍不明确。
  • 需要更可靠的数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Little is known about the natural history of sporadic angiomyolipomas (AMLs); there is uncertainty regarding the indications of treatment and treatment options. OBJECTIVE: To evaluate the indications, effectiveness, harms, and follow-up of different management modalities for sporadic AML to provide guidance for clinical practice. EVIDENCE ACQUISITION: A systematic review of the literature was undertaken, incorporating Medline, Embase, and the Cochrane Library (from 1 January 1990 to 30 June 2017), in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. No restriction on study design was imposed. Patients with sporadic AML were included. The main interventions included active surveillance, surgery (nephron-sparing surgery and radical nephrectomy), selective arterial embolisation, and percutaneous or laparoscopic thermal ablations (radiofrequency, microwaves, or cryoablation). The outcomes included indications for active treatment, AML growth rate, AML recurrence rate, risk of bleeding, post-treatment renal function, adverse events of treatments, and modalities of follow-up. Risk of bias assessment was performed using standard Cochrane methods. EVIDENCE SYNTHESIS: Among 2704 articles identified, 43 were eligible for inclusion (zero randomised controlled trials, nine nonrandomised comparative retrospective studies, and 34 single-arm case series). Most studies were retrospective and uncontrolled, and had a moderate to high risk of bias. CONCLUSIONS: In active surveillance series, spontaneous bleeding was reported in 2% of patients and active treatment was undertaken in 5%. Active surveillance is the most chosen option in 48% of the cases, followed by surgery in 31% and selective arterial embolisation in 17% of the cases. Selective arterial embolisation appeared to reduce AML volume but required secondary treatment in 30% of the cases. Surgery (particularly nephron-sparing surgery) was the most effective treatment in terms of recurrence and need for secondary procedures. Thermal ablation was an infrequent option. The association between AML size and the risk of bleeding remained unclear; as such the traditional 4-cm cut-off should not per se trigger active treatment. In spite of the limitations and uncertainties relating to the evidence base, the findings may be used to guide and inform clinical practice, until more robust data emerge. PATIENT SUMMARY: Sporadic angiomyolipoma (AML) is a benign tumour of the kidney consisting of a mixture of blood vessels, fat, and muscle. Large tumours may have a risk of spontaneous bleeding. However, the size beyond which these tumours need to be treated remains unclear. Most small AMLs can be monitored without any active treatment. For those who need treatment, options include surgical removal of the tumour or stopping its blood supply (selective embolisation). Surgery has a lower recurrence rate and lower need for a repeat surgical procedure.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Fernández-Pello S, Hora M, Kuusk T, et al. Management of Sporadic Renal Angiomyolipomas: A Systematic Review of Available Evidence to Guide Recommendations from the European Association of Urology Renal Cell Carcinoma Guidelines Panel. Eur Urol Oncol. 2019. PMID: 31171501. doi:10.1016/j.euo.2019.04.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。